Metformin/voglibose - Novartis

Drug Profile

Metformin/voglibose - Novartis

Alternative Names: VingoseMet; Voglibose/metformin - Novartis

Latest Information Update: 29 Sep 2015

Price : *
* Final gross price and currency may vary according to local VAT and billing address.

At a glance

  • Originator Novartis
  • Developer Athena Drug Delivery Solutions; Novartis
  • Class Antihyperglycaemics; Biguanides; Inositol phosphates; Small molecules; Sugar alcohols
  • Mechanism of Action Alpha-glucosidase inhibitors; AMP activated protein kinase stimulants; Gluconeogenesis inhibitors; Glucose modulators
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity No

Highest Development Phases

  • Marketed Diabetes mellitus

Most Recent Events

  • 29 Sep 2015 Launched for Diabetes mellitus (PO) (before September 2015)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top